ASCO® GI Symposium 2023

HER2-low tumors are not well characterized among gastric or gastroesophageal junction adenocarcinomas. More importantly, this patient population is currently treated as HER2-negative without anti-HER-2 directed therapy. This poster leveraged Tempus’ multimodal database to describe a real-world outcome analysis of this distinct genomically defined underrepresented population.

HER2/ERBB2 is a known therapeutic target in gastroesophageal adenocarcinoma (GEAC). HER3/ERBB3 is an emerging target in a variety of cancers but less defined in GEAC. This poster uses Tempus multimodal data to provide insights into the genomic and immunologic landscape of ERBB2/ERBB3 alterations in GEAC.

Both in vitro/in vivo, Tmod chimeric antigen receptor (CAR) T-cell therapy kills cells with HLA-A02 LOH (tumor) without harming cells with retained HLA-A02 expression (normal). However, HLA-A02 LOH can only be therapeutically exploited if patients are identifiable through a feasible and timely clinical workflow. We established a biobanking protocol (BASECAMP-1, NCT04981119) and determined this prospective HLA-A02 LOH identification strategy is achievable in the real-world setting.

Previous research has demonstrated differences in responses to checkpoint inhibitors between liver and non-liver metastases in microsatellite stable metastatic colorectal cancer (mCRC). This poster leverages Tempus’ multimodal database to investigate differences in tumor microenvironment and mutational landscape of CRC primary and metastatic sites.

The progression of neoplasia in colorectal cancer (CRC) has been well characterized, with the evolution typically involving mutations in APC, KRAS, and p53, among others. POLE/POLD1 genes encode for proteins essential in enzymatic DNA polymerase function, yet POLE/POLD1 mutations in tumors are poorly characterized. This poster uses Tempus’ multimodal database to describe POLE/POLD1 alterations in a large, real-world cohort of patients with CRC.

The recent development of KRAS G12C inhibitors underscores the potential to target KRAS mutations. Right-sided and left-sided colon tumors exhibit different molecular features. This poster uses Tempus multimodal data to characterize the prevalence of KRAS variants, interrelation with primary tumor location, and association with immune biomarkers in CRC.